The study was conducted by a team led by Barbosa, B.B. and collaborators Arruda, G.F.C.d. and Jimenez, M.L.J. Their investigation, published in BMC Health Services Research, points to significant systematic biases that compromise the quality of care provided to individuals with larger body sizes. Through mixed methodologies—a qualitative analysis coupled with quantitative data—the researchers paint a vivid picture of the pervasive nature of fatphobia entrenched within health care settings. They chronicle the stories of patients who have encountered prejudice from medical professionals, revealing shocking encounters that highlight an alarming disconnect between healthcare ethics and practice.

During their research, the team identified alarming attitudes among healthcare professionals concerning weight. Many professionals expressed judgments about patients’ lifestyles or self-discipline, attributing health outcomes solely to an individual’s body size rather than a complex interplay of genetics, environment, and socio-economic factors. This prejudgment leads to misdiagnosis and inappropriate treatment plans, compromising the quality of care offered to larger patients. Patients disproportionately report feelings of humiliation and betrayal when confronted by this bias, raising ethical concerns about equitable healthcare access.

The qualitative portion of the study utilized in-depth interviews allowing healthcare professionals to articulate their own biases and misconceptions surrounding fatness. These narratives provided critical insights into the training and educational practices that contributed to these entrenched beliefs. Surprisingly, many practitioners acknowledged their own biases as a learned behavior reinforced during their formative years in medical education. Such admissions underscore the necessity for systemic changes within medical curricula to tackle and rectify the ingrained biases that jeopardize patient care.

Moreover, the researchers highlighted how societal norms and media representations exacerbate these biases among healthcare practitioners. With predominant imagery in health discourse often centered on thinness as an ideal, it breeds a culture where larger bodies are seen as a failure of personal responsibility rather than an aspect of individual diversity. This attitudinal framework ultimately influences the care received by bigger patients, leading to a cycle of stigma and poor health outcomes.

Through quantitative evaluation, the study underlined statistical evidence of the biases affecting patient care. Survey results from both healthcare professionals and patients revealed a troubling correlation between healthcare professionals’ biases and patients’ reported dissatisfaction with care. The data reflected a clear pattern where larger patients were more likely to receive inadequate counsel, experience longer waiting times, and report feelings of dismissal during medical consultations compared to their slimmer counterparts.

Furthermore, the findings provoke a vital conversation around accountability in healthcare settings. Should healthcare professionals be trained to confront their biases? Should institutions implement specific protocols to ensure equitable treatment? These questions are fundamental as the study advocates for institutional reforms that could promote inclusivity and cultural competence within healthcare practices. Enhancing training programs to incorporate fat studies could foster a greater understanding among professionals, steering them away from judgment and towards compassionate and holistic care.

Ultimately, Barbosa and colleagues advocate for an urgent need to dismantle spaces of fatphobia within healthcare settings. By reformulating training programs to incorporate discussions on body diversity, healthcare institutions stand a greater chance to provide adequate, unbiased care. Such reforms could not only improve patient outcomes but also contribute to overall societal shifts in how bodies are perceived and treated within the healthcare system.

In conclusion, the findings of this mixed-method study serve as a clarion call for immediate action. By lobbying for systemic changes and fostering a culture of awareness within healthcare training, it is possible to alleviate the adverse effects of fatphobia. As society endeavors towards advancing equity in health, it is paramount for healthcare professionals and institutions to acknowledge and address their biases, ultimately working towards a more inclusive health landscape. This element of research shines a necessary light on an issue too often shrouded in silence, prompting both professionals and patients to partake in shaping a more just healthcare experience.

The pivotal research conducted in Brazil highlights the urgent need for a paradigm shift within healthcare practices, emphasizing the importance of training healthcare professionals not only in clinical skills but also in cultural competence and sensitivity towards body diversity. By recognizing fatphobia as a prevailing issue, we open the door to healthier patient-provider relationships and improved health outcomes for individuals of all body sizes.

Subject of Research: Structural fatphobia in the training and practice of primary health care professionals in Brazil.

Article Title: Structural fatphobia in the training and practice of primary health care professionals in Brazil: a mixed-methods study grounded in fat studies.

Article References:

Barbosa, B.B., Arruda, G.F.C.d., Jimenez, M.L.J. et al. Structural fatphobia in the training and practice of primary health care professionals in Brazil: a mixed-methods study grounded in fat studies.
BMC Health Serv Res (2026). https://doi.org/10.1186/s12913-026-14022-2

Image Credits: AI Generated

DOI: 10.1186/s12913-026-14022-2

Keywords: Fatphobia, healthcare bias, patient care, primary health care, medical education.

Hepatocellular carcinoma remains one of the most prevalent malignancies worldwide and carries a notoriously high recurrence rate following surgical resection. Such recurrences often present as unresectable lesions, demanding alternative therapeutic approaches. Despite advances in loco-regional therapies, no standardized treatment regimen currently exists for managing recurrent unresectable HCC, highlighting an urgent unmet clinical need.

The study, published in BMC Cancer, retrospectively analyzed clinical data from 83 patients diagnosed with recurrent unresectable HCC after initial surgery. The patients were stratified into three distinct treatment cohorts based on their regimens: a group receiving HAIC combined with TKIs and PD-1 inhibitors (HTP), a second group treated with TACE in combination with TKIs and PD-1 inhibitors (TTP), and a third control group undergoing TACE alone. This design enabled a robust comparative assessment of treatment efficacy and safety among cutting-edge combination therapies versus standard intervention.

HAIC and TACE are both hepatic artery-targeted therapies aimed at delivering chemotherapeutic agents directly to liver tumors, thereby maximizing local antitumor activity while limiting systemic toxicity. Combining these modalities with TKIs, which inhibit angiogenesis and tumor proliferation pathways, alongside PD-1 inhibitors that unleash anti-tumor immune responses, represents an innovative multimodal approach to tackle tumor progression on multiple fronts simultaneously.

The primary endpoint assessed was progression-free survival (PFS), a critical measure reflecting the duration during which patients remained free from disease advancement. Results revealed a marked improvement in median PFS among patients receiving combination therapy. Specifically, the HTP group demonstrated a median PFS of 13.7 months, substantially longer than the 9.2 months observed in the TTP group and dramatically exceeding the 2.5 months recorded for those treated with TACE alone. These findings underscore the additive benefit of incorporating both TKIs and PD-1 inhibitors alongside hepatic arterial infusion strategies.

Beyond survival metrics, tumor response was meticulously evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST), a standard for assessing therapeutic efficacy in HCC that accounts for changes in viable tumor tissue. The disease control rate (DCR), encompassing complete response (CR), partial response, and stable disease, was significantly higher in the HTP cohort at 89.7%, compared to 75.0% in the TTP group and only 50.0% with TACE monotherapy. The objective response rate (ORR), indicative of measurable tumor shrinkage, also favored combination regimens, reaching 44.8% and 35% in the HTP and TTP groups respectively, versus a mere 14.7% in the control group.

Remarkably, the incidence of complete response was restricted to the HTP group, with 17.2% of patients achieving this outcome. This contrasts starkly with a complete response rate of zero in both the TTP and TACE alone arms. Such results suggest that HAIC, when synergized with TKIs and PD-1 checkpoint blockade, may elicit profound antitumor effects potentially capable of eradicating clinically evident disease in a subset of patients.

Safety profiles across treatment arms were carefully monitored, revealing no occurrences of serious adverse reactions within the HTP and TTP groups. This highlights the tolerability of these combination regimens, which is pivotal considering the typically compromised hepatic reserve and overall frailty of advanced HCC patients. The absence of severe toxicity supports the feasibility of integrating immunotherapy and targeted agents with locoregional chemotherapy in clinical practice.

Mechanistically, the therapeutic synergy observed likely stems from complementary modes of action. TKIs suppress tumor angiogenesis and cellular proliferation, thereby restricting nutrient supply and direct tumor growth. PD-1 inhibitors enhance the host immune system’s capacity to recognize and destroy cancer cells by preventing immune checkpoint-mediated T cell exhaustion. Concurrently, HAIC and TACE deliver localized cytotoxic chemotherapy that induces tumor necrosis. This concerted attack disrupts the tumor microenvironment, potentially overcoming resistance mechanisms seen with monotherapy.

This study’s implications extend far beyond survival statistics. It emphasizes the evolving landscape of HCC treatment, where integrating systemic immunomodulation and targeted therapy with traditional intra-arterial chemotherapy heralds a new era of personalized oncology. Identifying patients most likely to benefit from such regimens remains an ongoing challenge, necessitating further biomarker-driven investigations.

Despite its retrospective design and relatively modest sample size, the research offers compelling evidence warranting prospective, randomized clinical trials to validate these findings. The ability to induce complete responses in previously refractory recurrent HCC patients could translate into durable remissions and improved overall survival, transforming standard care paradigms.

In summary, the combination of TKIs and PD-1 inhibitors with HAIC or TACE demonstrates superior efficacy and safety compared to TACE alone in treating recurrent unresectable hepatocellular carcinoma. Particularly, HAIC combined with these systemic agents achieves the highest complete response rates, shedding light on promising therapeutic avenues. As liver cancer continues to pose formidable clinical challenges, these findings pave the way toward more effective, multimodal treatment strategies that improve patient outcomes and quality of life.

Future research should aim to elucidate the molecular underpinnings driving response heterogeneity and resistance, optimize dosing schedules, and evaluate long-term survivorship benefits. Moreover, integrating advanced imaging modalities and liquid biopsy approaches may facilitate early detection of treatment response and recurrence, further refining clinical decision-making. Ultimately, multidisciplinary collaboration will be key to translating these scientific insights into routine clinical application.

The study stands as a testament to the rapidly advancing frontier of oncological therapeutics, underscoring the power of combining precision medicine, immunotherapy, and locoregional interventions. As these innovations converge, they offer renewed optimism for patients confronting the formidable challenge of recurrent unresectable hepatocellular carcinoma.

Subject of Research: Treatment efficacy and safety of tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors combined with hepatic arterial infusion chemotherapy/transarterial chemoembolization for recurrent unresectable hepatocellular carcinoma.

Article Title: The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.

Article References:
Deng, W., Xie, J., Wang, T. et al. The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma. BMC Cancer 25, 779 (2025). https://doi.org/10.1186/s12885-025-14185-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14185-x